NantKwest, Inc. (NASDAQ:NK) has been given a $3.00 price objective by investment analysts at Citigroup Inc. in a research note issued to investors on Monday. The brokerage presently has a “sell” rating on the biotechnology company’s stock. Citigroup Inc.’s price objective would suggest a potential downside of 48.98% from the stock’s current price.

A number of other research analysts have also issued reports on the stock. Jefferies Group LLC set a $4.00 target price on shares of NantKwest and gave the company a “hold” rating in a report on Monday, May 8th. Zacks Investment Research upgraded shares of NantKwest from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a report on Tuesday, May 16th. ValuEngine upgraded shares of NantKwest from a “strong sell” rating to a “sell” rating in a report on Wednesday, June 14th. Finally, BidaskClub lowered shares of NantKwest from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $10.79.

Shares of NantKwest (NASDAQ NK) opened at 5.88 on Monday. The firm’s market capitalization is $467.11 million. NantKwest has a 52-week low of $2.71 and a 52-week high of $9.60. The company’s 50-day moving average is $6.79 and its 200 day moving average is $4.88.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/nantkwest-inc-nasdaqnk-given-a-3-00-price-target-at-citigroup-inc/1489613.html.

In other news, Director Steve Gorlin sold 40,000 shares of the company’s stock in a transaction dated Tuesday, June 20th. The shares were sold at an average price of $7.78, for a total transaction of $311,200.00. Following the completion of the transaction, the director now owns 409,725 shares of the company’s stock, valued at approximately $3,187,660.50. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 70.19% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of NK. Renaissance Technologies LLC increased its stake in NantKwest by 1,884.1% in the first quarter. Renaissance Technologies LLC now owns 486,100 shares of the biotechnology company’s stock worth $1,726,000 after buying an additional 461,600 shares during the period. Vanguard Group Inc. increased its stake in NantKwest by 8.4% in the first quarter. Vanguard Group Inc. now owns 2,082,706 shares of the biotechnology company’s stock worth $7,394,000 after buying an additional 160,510 shares during the period. Northern Trust Corp increased its stake in NantKwest by 67.8% in the second quarter. Northern Trust Corp now owns 304,062 shares of the biotechnology company’s stock worth $2,308,000 after buying an additional 122,906 shares during the period. State Street Corp increased its stake in NantKwest by 52.9% in the second quarter. State Street Corp now owns 341,007 shares of the biotechnology company’s stock worth $2,589,000 after buying an additional 117,946 shares during the period. Finally, Alps Advisors Inc. acquired a new stake in NantKwest during the second quarter worth about $563,000. 20.73% of the stock is owned by institutional investors.

NantKwest Company Profile

Analyst Recommendations for NantKwest (NASDAQ:NK)

Receive News & Ratings for NantKwest Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.